New recommendations for cholesterol management have emerged, suggesting a more proactive approach. One key aspect is that all adults should undergo a single test for lipoprotein(a), a genetic marker associated with heart disease.
Released by the American Heart Association and the American College of Cardiology, these updated guidelines aim to improve how doctors evaluate cardiovascular risks. This is particularly important since cardiovascular disease remains the leading cause of death in the U.S. for both men and women.
Dr. Roger Blumenthal, a cardiologist at Johns Hopkins and the leader of the committee that created the guidelines, emphasized that a significant portion of cardiovascular conditions—over 80%—can be prevented. He particularly pointed out the role of elevated LDL cholesterol, commonly known as the “bad” cholesterol.
However, relying solely on LDL levels may not provide a full picture, Blumenthal noted. Additional biomarker assessments can offer greater insight into cardiovascular risk, helping decide when to initiate lipid-lowering treatments.
Among the new directives is the recommendation for a one-time lipoprotein(a) test for everyone. This simple blood test is widely available and is increasingly offered by many primary care physicians as part of routine preventive care.
Since lipoprotein(a) levels are largely determined by genetics and tend to remain stable throughout one’s life, the test is typically only necessary once, ideally in early adulthood. High levels of lipoprotein(a) indicate an inherited predisposition to heart attacks and strokes, among other cardiovascular issues.
The guidelines also advocate for increased use of coronary calcium scoring, a non-invasive scan that detects calcified plaque in the arteries. Furthermore, they encourage the use of a risk assessment tool called PREVENT, which estimates both 10-year and 30-year risks for heart disease, aiding in medication-related decisions.
Statins, the standard medication for lowering cholesterol, continue to be recommended. The updated guidelines suggest that these medications might also be appropriate for individuals with lower perceived risks based on their overall lifetime risk profile.
“This represents a significant change,” commented Dr. Steven Nissen from the Cleveland Clinic. He stressed that evaluating a person’s lifetime risk is crucial.
According to Nissen, the new guidelines are likely to lead to early treatment for many individuals. Given that generic versions of statins are accessible and quite affordable—he himself pays about $3 monthly for his prescription—it becomes a practical choice for many.
It’s estimated that around 25% of U.S. adults have elevated LDL cholesterol levels, which can raise their risk of serious heart-related events. Nissen believes that the new guidelines will benefit millions, leading to increased use of statins and other medications to reduce LDL levels, which could notably lower heart attacks and strokes.
The recommendations reiterate the importance of lifestyle changes as well. Regular exercise, quitting smoking, and maintaining good sleep habits are essential for heart health. As Leslie Cho, another preventive cardiologist at the Cleveland Clinic, puts it, diet and exercise are fundamental to effective cardiac prevention.
These guidelines are documented in the journal Circulation and in the Journal of the American College of Cardiology.
